Date: 2014-10-27
Type of information: Termination of the agreement
Compound: REMOXY™ (oxycodone)
Company: Pfizer (USA - NY) Pain Therapeutics (USA - TX)
Therapeutic area: CNS diseases
Type agreement: termination
Action mechanism:
Disease: moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time
Details: * On October 27, 2014, Pfizer has notified Pain Therapeutics that it has decided to discontinue its agreement to develop and commercialize REMOXY™ (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc. Pfizer has concluded an internal review of the top-line results of five recently completed clinical studies required to address the Complete Response Letter received in June 2011 from the FDA. Pfizer and Pain Therapeutics will work together for an orderly transition of REMOXY to Pain Therapeutics. Pfizer will continue ongoing activities under the agreement for the next six months until the scheduled termination date.
Financial terms:
Latest news:
